Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2021-09-17

2021

Stournara Lambrini

Κων/νος Ν. Συρίγος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αδάμ Αδαμόπουλος, Επικ. Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γεώργιος Μπάμιας, Αν. Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Η κλινική σημασία της μέτρησης του εκπνεόμενου κυψελιδικού μονοξειδίου του αζώτου σε ασθενείς με μη μικροκυτταρικό καρκίνο πνεύμονα υπό ανοσοθεραπεία

Greek

Clinical significance of exhaled nitic oxide in non -small cell lung cancer patients on immunotherapy treatment

Introduction: Measurement of exhaled nitric oxide (NO) is a non-invasive, well standardized, simple technique and is regarded as a potential tool for screening and follow-up of chest diseases. The presence of NO as a marker of airway inflammation and indirectly as a general indicator of inflammation and oxidative stress plays an important role in carcinogenesis. Immunotherapy has been shown to improve survival in non-small cell lung cancer (NSCLC).
Objectives: This prospective study aimed to investigate whether immunotherapy altered lung inflammation and pulmonary function in NSCLC patients. Furthermore, correlation levels of NO with other markers of inflammation were investigated.
Method: We studied 26 patients 15 men and 11 women with NSCLC stage IV. We analysed blood tests for control of inflammatory markers, functional pulmonary tests and alveolar exhaled nitric oxide. Only 8 patients completed the study with measurements before administration of immunotherapy and after 4 cycles.
Results: Mean NO value before immunotherapy administration was 14,2, while mean NO after 4 cycles of immunotherapy was 12,5. This reduction in mean NO levels was not clinically significant and did not correlate with inflammatory markers.
Conclusions: Nitric oxide (NO), a small molecule derived from L-arginine, has been demonstrated to participate in inflammation, tumor immunity and tumor apoptosis, as well as other pathophysiological process, which are associated with the pathogenesis and progression of lung cancer. Τhis study failed to demonstrate clinically significant mean NO reduction after 4 cycles of immunotherapy and to correlate inflammatory markers. The sample size is very small and the fact that NO is an indicator of airway inflammation in chronic airway diseases such as COPD and asthma, coexisting diseases might leαd to confusing results. Emerging studies have been carried out to evaluate whether NO can be regarded as a novel marker for lung cancer. However, controversial results were observed among these studies.

Health Sciences

Exhaled nitric oxide (NO), FeNO, NSCLC, Lung cancer, Immunotherapy

No

0

Yes

158

123

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2960812